WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598283

CAS#: 133242-30-5

Description: Landiolol is a highly cardioselective ultra short-acting beta-blocker.

Chemical Structure

CAS# 133242-30-5

Theoretical Analysis

MedKoo Cat#: 598283
Name: Landiolol
CAS#: 133242-30-5
Chemical Formula: C25H39N3O8
Exact Mass: 509.2737
Molecular Weight: 509.6
Elemental Analysis: C, 58.92; H, 7.71; N, 8.25; O, 25.12

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 144481-98-1 (HCl)   133242-30-5 (Free base)  

Synonym: Landiolol; ONO-1101; ONO 1101; ONO1101;

IUPAC/Chemical Name: (2,2-dimethyl-1,3-dioxolan-4-yl)methyl 3-(4-((S)-2-hydroxy-3-((2-(morpholine-4-carboxamido)ethyl)amino)propoxy)phenyl)propanoate


InChi Code: InChI=1S/C25H39N3O8/c1-25(2)35-18-22(36-25)17-34-23(30)8-5-19-3-6-21(7-4-19)33-16-20(29)15-26-9-10-27-24(31)28-11-13-32-14-12-28/h3-4,6-7,20,22,26,29H,5,8-18H2,1-2H3,(H,27,31)/t20-,22?/m0/s1


Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

Preparing Stock Solutions

The following data is based on the product molecular weight 509.6 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.


Dilution Calculator

Calculate the dilution required to prepare a stock solution.

1: Okajima M, Takamura M, Taniguchi T. Landiolol, an ultra-short-acting β1-blocker, is useful for managing supraventricular tachyarrhythmias in sepsis. World J Crit Care Med. 2015 Aug 4;4(3):251-7. doi: 10.5492/wjccm.v4.i3.251. eCollection 2015 Aug 4. PubMed PMID: 26261777; PubMed Central PMCID: PMC4524822.

2: Xiao J, He P, Zou Q, Zhao Y, Xue Z, Deng X, Li S, Guo Q, Tao G, Yang T, Lang Z, He J, Wang X. Landiolol in the treatment of the intraoperative supraventricular tachycardia: a multicenter, randomized, double-blind, placebo-controlled study. J Clin Anesth. 2015 Mar;27(2):120-8. doi: 10.1016/j.jclinane.2014.07.003. Epub 2014 Nov 28. PubMed PMID: 25434501.

3: Kunisawa T, Yamagishi A, Suno M, Nakade S, Higashi R, Kurosawa A, Sugawara A, Matsubara K, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in gynecologic patients. J Anesth. 2015 Apr;29(2):198-205. doi: 10.1007/s00540-014-1908-5. Epub 2014 Sep 4. PubMed PMID: 25186494.

4: Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Impacts of patient characteristics on the effectiveness of landiolol in AF/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. Adv Ther. 2014 Apr;31(4):426-39. doi: 10.1007/s12325-014-0111-2. Epub 2014 Mar 19. Erratum in: Adv Ther. 2014 May;31(5):577-8. PubMed PMID: 24643403; PubMed Central PMCID: PMC4003342.

5: Ishigaki D, Arimoto T, Iwayama T, Hashimoto N, Kutsuzawa D, Kumagai Y, Nishiyama S, Takahashi H, Shishido T, Miyamoto T, Watanabe T, Kubota I. Prevention of immediate recurrence of atrial fibrillation with low-dose landiolol after radiofrequency catheter ablation. J Arrhythm. 2015 Oct;31(5):279-85. doi: 10.1016/j.joa.2015.02.003. Epub 2015 Apr 4. PubMed PMID: 26550083; PubMed Central PMCID: PMC4600890.

6: Mori K, Yamada K, Fukuda T, Mitsui T, Kitamura T, Yamaguchi D, Ando J, Wada I, Nomura S, Shimizu N, Seto Y. Landiolol hydrochloride for early postoperative tachycardia after transthoracic esophagectomy. Surg Today. 2014 May;44(5):848-54. doi: 10.1007/s00595-013-0615-4. Epub 2013 May 15. PubMed PMID: 23674201.

7: Li L, Ai Q, Lin L, Ge P, Yang C, Zhang L. Efficacy and safety of landiolol for prevention of atrial fibrillation after cardiac surgery: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015 Jul 15;8(7):10265-73. eCollection 2015. Review. PubMed PMID: 26379818; PubMed Central PMCID: PMC4565201.

8: Wang M, Zhang Q, Hua W, Zhou W, Huang M, Wang H. Pharmacokinetics, pharmacodynamics, and safety of landiolol hydrochloride in healthy Chinese subjects. Drug Res (Stuttg). 2014 Mar;64(3):141-5. doi: 10.1055/s-0033-1354368. Epub 2013 Sep 3. PubMed PMID: 24002929.

9: Sakamoto A, Hamasaki T, Kitakaze M. Perioperative landiolol administration reduces atrial fibrillation after cardiac surgery: A meta-analysis of randomized controlled trials. Adv Ther. 2014 Apr;31(4):440-50. doi: 10.1007/s12325-014-0116-x. Epub 2014 Apr 23. PubMed PMID: 24756366; PubMed Central PMCID: PMC4003343.

10: Sezai A, Osaka S, Yaoita H, Ishii Y, Arimoto M, Hata H, Shiono M. Safety and efficacy of landiolol hydrochloride for prevention of atrial fibrillation after cardiac surgery in patients with left ventricular dysfunction: Prevention of Atrial Fibrillation After Cardiac Surgery With Landiolol Hydrochloride for Left Ventricular Dysfunction (PLATON) trial. J Thorac Cardiovasc Surg. 2015 Oct;150(4):957-64. doi: 10.1016/j.jtcvs.2015.07.003. Epub 2015 Jul 10. PubMed PMID: 26254752.

11: Kunisawa T, Yamagishi A, Suno M, Nakade S, Honda N, Kurosawa A, Sugawara A, Tasaki Y, Iwasaki H. Target-controlled infusion and population pharmacokinetics of landiolol hydrochloride in patients with peripheral arterial disease. Ther Clin Risk Manag. 2015 Jan 17;11:107-14. doi: 10.2147/TCRM.S74867. eCollection 2015. PubMed PMID: 25653534; PubMed Central PMCID: PMC4303402.

12: Niwa Y, Koike M, Iwata N, Kobayashi D, Tanaka C, Fujii T, Nakayama G, Sugimoto H, Fujiwara M, Kodera Y. Effect of landiolol hydrochloride on tachyarrhythmia after esophagectomy. Hepatogastroenterology. 2014 Sep;61(134):1546-51. PubMed PMID: 25436340.

13: Hirano M, Yamashina A, Hara K, Ikari Y, Jinzaki M, Iino M, Yamaguchi T, Tanimoto M, Kuribayashi S; Landiolol Hydrochloride Study Group. A randomized, double-blind, placebo-controlled, phase III study of the short-acting β1-adrenergic receptor blocker landiolol hydrochloride for coronary computed tomography angiography in Japanese patients with suspected ischemic cardiac disease. Clin Drug Investig. 2014 Jan;34(1):53-62. doi: 10.1007/s40261-013-0149-y. PubMed PMID: 24174275; PubMed Central PMCID: PMC3889825.

14: Plosker GL. Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias. Drugs. 2013 Jun;73(9):959-77. doi: 10.1007/s40265-013-0077-4. Review. Erratum in: Drugs. 2013 Jul;73(11):1255. PubMed PMID: 23760735.

15: Nakamura Y, Yamaji K, Saho T, Matsuzaki Z, Yuda I, Soga Y, Shirai S, Ando K, Nobuyoshi M. A comparison of bolus injection of landiolol versus oral administration of propranolol before cardiac computed tomography. Springerplus. 2014 Feb 17;3:93. doi: 10.1186/2193-1801-3-93. eCollection 2014. PubMed PMID: 24634807; PubMed Central PMCID: PMC3951651.

16: Aoyama H, Otsuka Y, Aoyama Y. Landiolol infusion during general anesthesia does not prevent postoperative atrial fibrillation in patients undergoing lung resection. Gen Thorac Cardiovasc Surg. 2016 Dec;64(12):735-741. Epub 2016 Aug 23. PubMed PMID: 27553581.

17: Krumpl G, Ulc I, Trebs M, Kadlecová P, Hodisch J. Pharmacokinetics and pharmacodynamics of two different landiolol formulations in a healthy Caucasian group. Eur J Pharm Sci. 2016 Sep 20;92:64-73. doi: 10.1016/j.ejps.2016.06.022. Epub 2016 Jun 29. PubMed PMID: 27373605.

18: Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, Shimizu W, Aiba T, Kitakaze M, Sakamoto A, Ikeda T, Imai Y, Daimon T, Fujino K, Nagano T, Okamura T, Hori M; J-Land Investigators. Urgent management of rapid heart rate in patients with atrial fibrillation/flutter and left ventricular dysfunction: comparison of the ultra-short-acting β1-selective blocker landiolol with digoxin (J-Land Study). Circ J. 2013;77(4):908-16. Epub 2013 Mar 15. PubMed PMID: 23502991.

19: Yamashita T, Saitoh T, Matsushita M. Design of a prospective observational survey on landiolol in atrial fibrillation/atrial flutter patients with chronic heart failure - AF-CHF landiolol survey. J Cardiol. 2015 Jul;66(1):69-72. doi: 10.1016/j.jjcc.2014.09.008. Epub 2014 Nov 6. PubMed PMID: 25454208.

20: Miyake K, Fujita Y, Yoshizawa S, Tomita M, Miyazu M, Sento Y, Yoshimura S, Sobue K. Effects of landiolol on refractory tachyarrhythmia after total cavopulmonary connection: a retrospective, observational, cohort study. J Anesth. 2016 Apr;30(2):331-6. doi: 10.1007/s00540-015-2119-4. Epub 2015 Dec 23. PubMed PMID: 26699148.